Automated Summary
Key Facts
On 11 December 2019, the Competition Tribunal of South Africa unconditionally approved a large merger transaction where Brimstone Investment Corporation Ltd (Brimstone) acquired sole control of Firefly Investments 306 (Pty) Ltd (Firefly) by purchasing 54.93% of its shares from Capitalworks Private Equity Partnership and Scientific Investments Partnership. Brimstone previously held 25% in Firefly, increasing its stake to 80% post-transaction. Firefly, a special purpose vehicle holding Obsidian Health (Pty) Ltd, supplies healthcare products in Sub-Saharan Africa with less than 5% market share. The Commission found no horizontal overlap or vertical concerns, noting competitors like Medtronic Africa and Philips SA Health Systems would maintain competitive constraints. The merger was deemed unlikely to cause job losses or adverse employment effects, as no duplication of roles was expected, and no public interest concerns were raised.
Issues
- The tribunal assessed whether the acquisition of Firefly by Brimstone would lead to a significant reduction in competition in the healthcare products market, particularly in cardiology, cardiovascular, theatre, ICU, and high care sectors. The Commission found no horizontal overlap and concluded the transaction would not substantially lessen competition.
- The tribunal evaluated public interest factors, including employment impacts. The merging parties stated no retrenchments are planned, and the Commission confirmed no employment concerns or other public interest issues were raised during the review process.
Holdings
- The Commission concluded the transaction does not create vertical relationships warranting concern, despite Brimstone's pre-existing non-controlling stake in Life Healthcare and supply relationships with Firefly.
- The Tribunal found no horizontal overlap in the activities of the merging parties, noted Firefly's less than 5% market share in medical devices, and acknowledged competitors like Medtronic and Philips SA Health Systems would maintain competitive constraints.
- The Tribunal confirmed the transaction will not cause employment losses or duplication of roles, as no retrenchments are planned and employee representatives raised no objections. No other public interest issues were found.
Remedies
The Competition Tribunal of South Africa unconditionally approved the large merger transaction whereby Brimstone Investment Corporation Ltd intends to acquire sole control of Firefly Investments 306 (Pty) Ltd. The approval was granted on 11 December 2019 with no conditions or remedies imposed.
Legal Principles
The Competition Tribunal applied the principle that a merger is not likely to result in a substantial lessening of competition if there is minimal market overlap and existing competitors can constrain market power. The assessment considered Firefly's less than 5% market share and the presence of major competitors like Medtronic and Philips.
Judge Name
- Enver Daniels
- Andiswa Ndoni
- Yasmin Carrim
Passage Text
- [18] We therefore unconditionally approved the proposed transaction.
- [15] Since this transaction only contemplates an increase in shareholding, it is unlikely that there will be a duplication of jobs. The Commission was therefore satisfied with the merging parties' views that no employment concerns will arise as a result of the proposed transaction.
- [12] In view of the above, the Commission concluded that the proposed transaction is not likely to result in any substantial lessening or prevention of competition in any market.